AUD/SUD was significant risk factor for HCC in pre-direct-acting antiviral era, and in the post-direct-acting antiviral era among those with active hepatitis C.

AT SABCS 2025, researchers presented surgical outcomes for patients who received 6 months of neoadjuvant endocrine therapy for ER-positive, HER2-negative breast cancer.

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.